Overview of documents, which are approved/acknowledged/left without any feedback by Institute on the field of Clinical Trials
Overview of possible ways of response of Institute to documents, which are submitted during Clinical Trial of human medicinal products to Clinical Trials Dpt.
WE APPROVE |
WE ACKNOWLEDGE |
WITHOUT FEEDBACK |
Substantial Amendment (SA) (with Covering Expenditures) |
Investigator´s Brochure Update (as non-SA) |
CRF (Case Report Form) |
Non-substantial Amendment (without Covering Expenditures) |
Protocol Deviation Alert |
Information on the Commencement of the CT |
New version of Information for Patient/Informed Consent Form (IP/ICF) |
Notification of Quality Defect (additional information required) |
CT Annual Progress Report |
Amendment to IP/ICF |
Urgent Safety Restriction (additional information required) |
DSUR/SUSAR/SAE line listings |
Amendment to Pharmaceutical Documentation (including shelf-life ext., new stability data, CoA, …) |
Dear Doctor Letter (as non-SA) |
Information about completion, suspension or early termination of the CT |
Form for Customs Purposes |
Notification onTemporary Halt of CT |
Summary report on the CT |
Dear Doctor Letter (as SA) |
Restart of CT |
Amended Protocol |
Change of Sponsor |
Information on the death of subject |
Patient´s Diary, Questionnaires, Cards, … |
Change of Legal Representative |
SmPC Update (if IMP has MA) |
Insurance Certificates |
Change in labeling Medicinal Product |
|
Advertisement, Advertising Materials |
Investigator´s Brochure Update (if SA – e.g. change of RSI) |
Change in center/New center (required submission of CTA – xml + signed hardcopy) |
|
Restart of CT
|
Change in Investigator (required submission of CTA – xml + signed hardcopy) |
|
Fulfilment of Mandatory Notice |
Change in CRO/contact person (required justification and statement from former CRO and from new CRO (including new PoA); effective date of this change; required submission of CTA – xml + signed hardcopy |
Legenda:
IP/ICF – Information for Patient / Informed Consent Form
CoA – Certificate of Analysis
RSI – Reference Safety Information
CT – Clinical Trial
SmPC – Summary of Medicinal Product Characteristics
IMP – Investigational Medicinal Product
MP – Medicinal Product
CRO – Contract Research Organisation
SUSAR – Suspected Unexpected Serious Adverse Reaction
SAE – Serious Adverse Event
CTA – Clinical Trial Application
Clinical Trials Department
28. 5. 2014